- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: MM-151 is a mixture of three fully human IgG1 monoclonal antibodies, each of which targets a distinct (and nonoverlapping) epitope on the extra-cellular domain of the EGFR . This can be termed an oligoclonal agent. It was designed to target EGFRs with treatment-induced (acquired) resistance mutations that develop in cancer patients treated with the approved anti-EGFR monoclonals cetuximab or panitumumab. Development of the three antibody components is reported in .
|We have tagged the EGFR as the primary molecular target of MM-151 based on preclinical results published in .
MM-151 antagonises high-affinity EGFR ligands more potently than cetuximab , and In cell viability studies, exhibits effective antiproliferative activity.
The P1X antibody component of MM-151 has an EGFR dissociation Kd of 0.071nM, the Kd for P2X is 0.3nM and for P3X is 0.011nM .
|Selectivity at catalytic receptors|
|Key to terms and symbols||Click column headers to sort|